My new workout plan is reminding me to take ‘messy action’

My new workout plan is reminding me to take ‘messy action’

My husband, Justin, works in fitness. Six months ago he opened a small-group personal training gym in our little Wisconsin town, and he’s been working to grow his membership, which now includes me. Something Justin talks about often with clients — while he’s discussing training, nutrition, or other lifestyle…

My twin has MG, and I have survivor’s guilt

Unearned guilt is one of the most useless emotions in the world. Guilt never has a full belly. It feeds eternally upon itself and adds to what’s there. Unearned guilt glues itself to the soul and wearily weighs it down. As the Depeche Mode song “Halo” says, guilt is like…

Inebilizumab reduces gMG severity in Phase 3 trial: Top-line data

Amgen’s antibody-based therapy inebilizumab reduces the severity of generalized myasthenia gravis (MG), according to top-line data from a Phase 3 clinical trial. Dubbed MINT (NCT04524273), the study showed inebilizumab’s therapeutic efficacy in gMG patients who test positive for self-reactive antibodies against the acetylcholine receptor (AChR) or muscle-specific…

Potential antibody therapy ARGX-119 may aid MuSK-MG patients

ARGX-119, an antibody designed to increase the activity of the muscle-specific kinase (MuSK) protein, protected against the development of neuromuscular disease in mice in a model of MuSK-associated myasthenia gravis (MG), and eased or reversed evident symptoms in animals with disease onset, scientists report. With further work, such an…

Anti-MuSK antibody levels may be MG severity, treatment biomarker

Blood levels of specific antibodies that target the muscle-specific tyrosine kinase (MuSK) may be biomarkers of disease severity and treatment response in people with myasthenia gravis (MG) who are positive for anti-MuSK antibodies. A study finds that high levels of MuSK-IgG4 — an anti-MuSK antibody subclass – were associated…